The wisdom community based on the new generation of information technology is the Xiaoshan stake in the construction of Wuxi City in 2012 cloud computing and networking applications demonstration projects, after nearly two years of construction, the successful completion of the project construction tasks.

The new generation of information technology researched in this project will break through the core technologies of cloud computing and IoT, such as virtualization, distributed storage, mass data management and so on. The research and development of massive data storage system, virtualized basic software, intelligent application management system And other core products, the establishment of multi-level and diversified information service system for the massive, for a new generation of demonstration and application of information technology to provide strong technical support.

The project's construction functions are designed around convenience and Huimin design so that the residents can enjoy the services of payment, purchase, ordering, housekeeping, home delivery, information release and inquiries without any out-of-community residents, and achieve home security alarm, Smart home, care for the elderly, health testing and care for the elderly, intelligent management of community properties, and communication channels between residents and property managers

Cabozantinib API

Cabozantinib is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.

Cabozantinib is a new molecular targeted drug developed by exelixis biopharmaceutical company in the United States. On November 29, 2012, the US Food and Drug Administration (FDA) approved cabotinib for the treatment of unresectable locally advanced or metastatic medullary thyroid carcinoma. In addition, sorafenib, van der nib and lovatinib are also approved by the food and Drug Administration (FDA) for the treatment of advanced thyroid cancer.

We are manufacturer of Cabozantinib Xl184 Malate in China, if you want to buy 14C Cabozantinib Api,Cabozantinib Xl184 Bms-907351,Cabozantinib Cas 849217-68-1 please contact us.

Cabozantinib Xl184 Malate,14C Cabozantinib Api,Cabozantinib Xl184 Bms-907351,Cabozantinib Cas 849217-68-1

 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com